ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss

Abied(ABMD)第三季度收益超出預期，營收錯失

Zacks Equity Research · 2020/02/05 16:00

Headquartered in Danvers, MA, ABIOMED Inc. (ABMD-Free Report) is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart.

總部設在馬薩諸塞州丹弗斯 AbiedInc.(aBMD-Free Report)從事醫療產品的開發、製造和營銷，旨在幫助或取代衰竭心臟的泵血功能。

Currently, ABIOMED has a Zacks Rank #4 (Sell) but that could change following its third quarter fiscal 2020 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here) the complete list of today’s Zacks #1 Rank stocks here). We have highlighted some of the key details from the just-released announcement below:

目前，ABIOMED的Zacks排名為第四(賣出)，但隨着剛剛發佈的2020財年第三季度收益報告的發佈，這種情況可能會改變。(你可以看到今天Zacks排名第一(強力買入)股票的完整名單，請點擊此處)今天Zacks排名第一的股票的完整名單，請點擊此處)。我們重點介紹了以下剛剛發佈的公告中的一些關鍵細節：

Earnings: ABIOMED reported third-quarter fiscal 2020 earnings per share (EPS) of $1.51, outpacing the Zacks Consensus Estimate of $1.09. The figure surged 55.7% year over year.

收益：Abied公佈2020財年第三季度每股收益(EPS)為1.51美元，超過Zacks普遍預期的1.09美元。這一數字同比飆升了55.7%。

Revenues: ABIOMED’s revenues came in at $221.6 million, which lagged the Zacks Consensus Estimate of $227 million. However, the metric improved 10.5% from the prior-year quarter.

收入：Abied的收入為2.216億美元，低於Zacks普遍預期的2.27億美元。然而，該指標比去年同期增長了10.5%。

ABIOMED, Inc. Price, Consensus and EPS Surprise

Abied，Inc.價格、共識和每股收益驚喜

20200206214140755d034r2e2e7i9g5s

Key Stats: U.S. Impella product revenues totaled $185.6 million, showing an increase of 8% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 5% in the quarter.

關鍵統計數據：美國Impella產品收入總計1.856億美元，同比增長8%。根據管理層的説法，本季度美國患者使用Impella心臟泵的數量上升了5%。

For fiscal 2020, ABIOMED expects revenues within $846-$877 million, mirroring an increase of 10-14%. This compares to the earlier-projected range of $885-$925 million, calling for an increase of 15-20% year over year.

ABIOMED預計2020財年收入在8.46億至8.77億美元之間，增幅為10%至14%。相比之下，早先的預測區間為8.85億-9.25億美元，要求同比增長15%-20%。

Check back later for our full write up on this ABIOMED report later!

檢查稍後再來看我們對這份ABIOMED報告的完整報道！

More Stock News: This Is Bigger than the iPhone!

更多股票新聞：這比iPhone還重要！

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

它可能成為所有技術革命之母。蘋果IPhone在10年內僅售出10億部，但一項新的突破預計將在短短3年內產生超過270億部設備，創造一個1.7萬億美元的市場。

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

扎克斯剛剛發佈了一份特別報告，強調了這一快速崛起的現象，併為利用這一現象提供了6個股票代碼。如果你不買現在，你可能會在2020年踢自己。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。